Difference between revisions of "CT Angiography Biomarker Ctte"
m (→Meetings) |
m |
||
| Line 1: | Line 1: | ||
| − | Co-chairs: Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT | + | '''Co-chairs''': Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT |
| − | Secretary: Julie Lisiecki | + | '''Secretary''': Julie Lisiecki |
* [http://tinyurl.com/QIBA-CT-Angiography-Roster Roster] | * [http://tinyurl.com/QIBA-CT-Angiography-Roster Roster] | ||
Revision as of 13:47, 15 August 2018
Co-chairs: Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT Secretary: Julie Lisiecki
Meetings
Recent Call Summaries:
Project Snapshot - CT Angiography
The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA).
Excerpt from the biomarker committee submission form:
The proposed QIBA Atherosclerosis Biomarkers Committee (ABC) will be composed of members from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Furthermore, stakeholders from different manufacturers will be included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee will develop technical performance standards to serve as atherosclerosis compositional biomarkers. Moreover, we will involve stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.